Andrea P Myers1, Virginia L Filiaci2, Yuping Zhang3, Michael Pearl4, Kian Behbakht5, Vicky Makker6, Parviz Hanjani7, Susan Zweizig8, James J Burke9, Gordon Downey10, Kimberly K Leslie3, Paul Van Hummelen11, Michael J Birrer12, Gini F Fleming13. 1. Dana Farber Cancer Institute, Boston, MA, United States. Electronic address: andrea.myers@novartis.com. 2. NRG Oncology Statistics and Data Management Center, Buffalo, NY, United States. 3. University of Iowa Hospitals and Clinics, Iowa City, IA, United States. 4. Stony Brook Medicine, Stony Brook, NY, United States. 5. Rush University Medical Center, Chicago, IL, United States. 6. Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States. 7. Abington Memorial Hospital, Gladwyne, PA, United States. 8. University of Massachusetts Memorial Health Care, Worcester, MA, United States. 9. Mercer University School of Medicine, Savannah, GA, United States. 10. Gynecologic Oncology of West Michigan, Grand Rapids, MI, United States. 11. Dana Farber Cancer Institute, Boston, MA, United States. 12. Massachusetts General Hospital/Dana Farber Cancer Center, Boston, MA, United States. 13. The University of Chicago Medical Center, Chicago, IL, United States.
Abstract
OBJECTIVE: Rapamycin analogs have reproducible but modest efficacy in endometrial cancer (EC). Identification of molecular biomarkers that predict benefit could guide clinical development. METHODS: Fixed primary tissue and whole blood were collected prospectively from patients enrolled on GOG 248. DNA was isolated from macro-dissected tumors and blood; next-generation sequence analysis was performed on a panel of cancer related genes. Associations between clinical outcomes [response rate (RR) 20%; progression-free survival (PFS) median 4.9months] and mutations (PTEN, PIK3CA, PIK3R1, KRAS, CTNNB1, AKT1, TSC1, TSC2, NF1, FBXW7) were explored. RESULTS: Sequencing data was obtained from tumors of 55 of the 73 enrolled pts. Mutation rates were consistent with published reports: mutations in PTEN (45%), PIK3CA (29%), PIK3R1 (24%), K-RAS (16%), CTNNB1 (18%) were common and mutations in AKT1 (4%), TSC1 (2%), TSC2 (2%), NF1 (9%) and FBXW7 (4%) were less common. Increased PFS (HR 0.16; 95% CI 0.01-0.78) and RR (response difference 0.83; 95% CI 0.03-0.99) were noted for AKT1 mutation. An increase in PFS (HR 0.46; 95% CI 0.20-0.97) but not RR (response difference 0.00, 95% CI -0.34-0.34) was identified for CTNNB1 mutation. Both patients with TSC mutations had an objective response. There were no statistically significant associations between mutations in PIK3CA, PTEN, PIK3R1, or KRAS and PFS or RR. CONCLUSIONS: Mutations in AKT1, TSC1 and TSC2 are rare, but may predict clinical benefit from temsirolimus. CTNNB1 mutations were associated with longer PFS on temsirolimus.
OBJECTIVE:Rapamycin analogs have reproducible but modest efficacy in endometrial cancer (EC). Identification of molecular biomarkers that predict benefit could guide clinical development. METHODS: Fixed primary tissue and whole blood were collected prospectively from patients enrolled on GOG 248. DNA was isolated from macro-dissected tumors and blood; next-generation sequence analysis was performed on a panel of cancer related genes. Associations between clinical outcomes [response rate (RR) 20%; progression-free survival (PFS) median 4.9months] and mutations (PTEN, PIK3CA, PIK3R1, KRAS, CTNNB1, AKT1, TSC1, TSC2, NF1, FBXW7) were explored. RESULTS: Sequencing data was obtained from tumors of 55 of the 73 enrolled pts. Mutation rates were consistent with published reports: mutations in PTEN (45%), PIK3CA (29%), PIK3R1 (24%), K-RAS (16%), CTNNB1 (18%) were common and mutations in AKT1 (4%), TSC1 (2%), TSC2 (2%), NF1 (9%) and FBXW7 (4%) were less common. Increased PFS (HR 0.16; 95% CI 0.01-0.78) and RR (response difference 0.83; 95% CI 0.03-0.99) were noted for AKT1 mutation. An increase in PFS (HR 0.46; 95% CI 0.20-0.97) but not RR (response difference 0.00, 95% CI -0.34-0.34) was identified for CTNNB1 mutation. Both patients with TSC mutations had an objective response. There were no statistically significant associations between mutations in PIK3CA, PTEN, PIK3R1, or KRAS and PFS or RR. CONCLUSIONS: Mutations in AKT1, TSC1 and TSC2 are rare, but may predict clinical benefit from temsirolimus. CTNNB1 mutations were associated with longer PFS on temsirolimus.
Authors: Gini F Fleming; Virginia L Filiaci; Brandon Marzullo; Richard J Zaino; Susan A Davidson; Michael Pearl; Vicky Makker; James J Burke; Susan L Zweizig; Linda Van Le; Parviz Hanjani; Gordon Downey; Joan L Walker; Henry D Reyes; Kimberly K Leslie Journal: Gynecol Oncol Date: 2014-01-20 Impact factor: 5.482
Authors: Brian M Slomovitz; Karen H Lu; Taren Johnston; Robert L Coleman; Mark Munsell; Russell R Broaddus; Cheryl Walker; Lois M Ramondetta; Thomas W Burke; David M Gershenson; Judith Wolf Journal: Cancer Date: 2010-08-02 Impact factor: 6.860
Authors: Meghan L Rudd; Jessica C Price; Sarah Fogoros; Andrew K Godwin; Dennis C Sgroi; Maria J Merino; Daphne W Bell Journal: Clin Cancer Res Date: 2011-01-25 Impact factor: 12.531
Authors: Amit M Oza; Laurie Elit; Ming-Sound Tsao; Suzanne Kamel-Reid; Jim Biagi; Diane Michele Provencher; Walter H Gotlieb; Paul J Hoskins; Prafull Ghatage; Katia S Tonkin; Helen J Mackay; John Mazurka; Joana Sederias; Percy Ivy; Janet E Dancey; Elizabeth A Eisenhauer Journal: J Clin Oncol Date: 2011-07-25 Impact factor: 44.544
Authors: S Y Han; H Kato; S Kato; T Suzuki; H Shibata; S Ishii; K Shiiba; S Matsuno; R Kanamaru; C Ishioka Journal: Cancer Res Date: 2000-06-15 Impact factor: 12.701
Authors: K Shoji; K Oda; S Nakagawa; S Hosokawa; G Nagae; Y Uehara; K Sone; Y Miyamoto; H Hiraike; O Hiraike-Wada; T Nei; K Kawana; H Kuramoto; H Aburatani; T Yano; Y Taketani Journal: Br J Cancer Date: 2009-06-02 Impact factor: 7.640
Authors: Yuexin Liu; Lalit Patel; Gordon B Mills; Karen H Lu; Anil K Sood; Li Ding; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine; Ilya Shmulevich; Russell R Broaddus; Wei Zhang Journal: J Natl Cancer Inst Date: 2014-09-10 Impact factor: 13.506
Authors: Carol Aghajanian; Virginia Filiaci; Don S Dizon; Jay W Carlson; Matthew A Powell; Angeles Alvarez Secord; Krishnansu S Tewari; David P Bender; David M O'Malley; Ashley Stuckey; JianJiong Gao; Fanny Dao; Robert A Soslow; Heather A Lankes; Kathleen Moore; Douglas A Levine Journal: Gynecol Oncol Date: 2018-05-24 Impact factor: 5.482
Authors: Helen J MacKay; Douglas A Levine; Victoria L Bae-Jump; Daphne W Bell; Jessica N McAlpine; Alessandro Santin; Gini F Fleming; David G Mutch; Kenneth P Nephew; Nicolas Wentzensen; Paul J Goodfellow; Oliver Dorigo; Hans W Nijman; Russell Broaddus; Elise C Kohn Journal: Oncotarget Date: 2017-08-03
Authors: Stephanie Lheureux; Carolyn McCourt; B J Rimel; Linda Duska; Gini Fleming; Helen Mackay; David Mutch; Sarah M Temkin; Jean Lynn; Elise C Kohn Journal: Gynecol Oncol Date: 2018-02-22 Impact factor: 5.304
Authors: Wei Wen; Gina Lowe; Cai M Roberts; James Finlay; Ernest S Han; Carlotta A Glackin; Thanh H Dellinger Journal: Sci Rep Date: 2017-10-06 Impact factor: 4.379